Oral & Tablets

Oral Research Peptides & Tablets

The oral and tablets category contains research compounds available in tablet or oral formulation rather than the lyophilized injectable format of most research peptides. This category includes both peptide-derived oral compounds and small-molecule research chemicals studied alongside peptides in metabolic and growth hormone research contexts.

Compounds in this category

• MK-677 (Ibutamoren) — Non-peptide growth hormone secretagogue. Small-molecule ghrelin receptor agonist with oral bioavailability, frequently studied alongside peptide-based GH secretagogues for comparison research.
• BPC-157 (Oral) — Oral formulation of BPC-157 for research on gastrointestinal stability and oral bioavailability studies.
• SLU-PP-332 — Synthetic small-molecule ERR (Estrogen-Related Receptor) agonist. Studied in metabolic research and exercise physiology contexts.

Research applications

The compounds in this category are studied in: oral bioavailability research, gastrointestinal absorption research, ghrelin receptor binding research, growth hormone secretagogue comparison studies, ERR pathway research, and metabolic research models. Oral formulations enable research designs that aren’t possible with injection-only compounds.

Quality standards at VialPepLab

Tablet formulations are verified for active compound content via HPLC analysis with content uniformity testing. MK-677 and SLU-PP-332 batches additionally verify by mass spectrometry given their small-molecule nature. Oral BPC-157 documents both peptide content and the oral delivery vehicle composition. Every batch ships with a COA documenting all measured parameters.

All compounds in this category are sold strictly for in-vitro laboratory research. Not for human or veterinary use.